Podcast Episodes

Back to Search
Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron
Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron

Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights? First, we dis…

4 years, 9 months ago

Short Long
View Episode
Episode 193: Jared Holz on Biotech's red tape, plus the latest billionaire science project
Episode 193: Jared Holz on Biotech's red tape, plus the latest billionaire science project

With biotech in the dumps, we talk to Oppenheimer analyst Jared Holz about why the world has soured on the sector and what it means for the future of…

4 years, 9 months ago

Short Long
View Episode
Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news
Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news

First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biog…

4 years, 9 months ago

Short Long
View Episode
Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict
Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict

First, emergency room physician Craig Spencer joins us to talk about how the Omicron variant is impacting New York City and what the coming months ha…

4 years, 9 months ago

Short Long
View Episode
Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review
Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review

We've come to our last episode of the year, and first, STAT’s Helen Branswell joins us to talk about Omicron, boosters, and the past and future of th…

4 years, 10 months ago

Short Long
View Episode
Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron
Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron

On this week's episode, we kick off the conversation with an update on what researchers are discovering about the Omicron variant of the coronavirus,…

4 years, 10 months ago

Short Long
View Episode
Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron
Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

Will the first Covid-19 pill be all that useful? How worrisome is Omicron? And when will it be safe to congregate? First, STAT's Matthew Herper join…

4 years, 11 months ago

Short Long
View Episode
Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving
Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving

First, epidemiologist Michael Osterholm of the University of Minnesota joins us to talk about Covid-19 case counts, vaccination rates, and the state …

4 years, 11 months ago

Short Long
View Episode
Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine
Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine

Rebecca Robbins of the New York Times joins us to discuss the escalating tension between Moderna and the National Institutes of Health over just who …

4 years, 11 months ago

Short Long
View Episode
Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga
Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga

STAT's Rachel Cohrs drops in to talk about the latest updates in drug pricing reform. Then, John Maraganore joins us to talk about his decision to st…

4 years, 11 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us